Skip to content
Funding & Disinvestments
-
Merck KGaA enters USD3B AI drug discovery partnership with Valo Health to target Parkinson’s disease
Through this partnership, Merck gains access to Valo’s advanced AI-powered human causal biology and discovery platforms, which the drugmaker will use to identify new disease targets and develop preclinical compounds.